Zenas BioPharma, Inc. Common Stock
$31.50
-$0.47 (-1.47%)
$31.25Day Range$32.04
Key Statistics
Market Cap
$2.05B
Shares Outstanding
65.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 13, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$32.04
Day High
$32.04
Day Low
$31.25
Volume
2.52M
VWAP
$31.51
Prev Close
$31.97
Transactions
--
Acc. Volume
--
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
PHARMACEUTICAL PREPARATIONSSIC 2834167 employees852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451857-271-2954IPO Sep 13, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001953926
- Composite FIGI
- BBG01J1MG9D6
- Share Class FIGI
- BBG01J1MG9F4
- Ticker Root
- ZBIO
- SIC Code
- 2834
About Zenas BioPharma, Inc. Common Stock (ZBIO) Stock
Zenas BioPharma, Inc. Common Stock (ZBIO) closed the 2026-09-18 session at $31.50, down 1.47% versus the previous close (-0.47). The stock opened at $32.04 and traded between $31.25 and $32.04 during that session. Session trading volume was 2.5M shares. The volume-weighted average price (VWAP) is $31.51.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Zenas BioPharma, Inc. Common Stock has a market capitalization of $2.05 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ZBIO is listed on the XNAS exchange. The company employs approximately 167 people. Zenas BioPharma, Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2024-09-13.
On this page you can find market ZBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.